Amid Bankruptcy Whispers, Purdue Pharma Seeks Delay of Okla. Opioid Trial
Purdue Pharma has sought to delay a May 28 trial against the Oklahoma AG, citing a “belated tidal wave of documents,” but the move comes amid reports of its possible Chapter 11 bankruptcy.
March 06, 2019 at 07:01 PM
5 minute read
The original version of this story was published on Law.com
Purdue Pharma has sought to delay a trial that is set to begin May 28 in Oklahoma, citing a “belated tidal wave of documents,” but the move comes amid reports that the opioid manufacturer could soon file for Chapter 11 bankruptcy.
In a case brought by the Oklahoma attorney general, the trial would be the first time a jury would decide whether Purdue was responsible for the opioid addiction crisis. Last week, Purdue filed a motion for continuance based on a massive data dump handed over by the attorney general's office. On Friday, Attorney General Mike Hunter countered that Purdue's motion was a ruse that, along with a potential bankruptcy filing, were all part of a “desperate” attempt to avoid trial.
“There is no way—no way—any of these defendants can face a jury,” wrote Hunter and the state's Oklahoma City attorneys, former federal judge Michael Burrage of Whitten Burrage, and Bradley Beckworth, co-head of Nix Patterson's complex litigation group. “Defendants know they can't hide anymore. Now they're trying to run.”
Purdue, in a reply Wednesday, chastised the “inflammatory rhetoric, speculation, and misleading, irrelevant assertions” raised in the attorney general's response.
Purdue's lawyers in the case are Sanford Coats of Crowe & Dunlevy in Oklahoma City and Mark Cheffo, a partner in Dechert's New York office.
Outside of court, the language on both sides was more tempered.
In an emailed statement, Hunter said, “Our focus over the next several months is on trial preparation and ensuring the facts and evidence in this case will be heard by Oklahoma triers of fact in an Oklahoma courtroom.”
Purdue spokesman Robert Josephson denied that the continuance motion had anything to do with a possible bankruptcy.
“We categorically deny that a failure to win the motion for a continuance will have a determinative effect on the company's decisions about whether or not to file for bankruptcy,” he wrote. “As previously stated, the company is looking at all of its options, but we have made no decisions, and have not set any timetables.”
On Monday, Reuters reported that Purdue Pharma was exploring bankruptcy to address its growing liabilities over the opioid epidemic. A Chapter 11 filing would halt the lawsuits, folding them into bankruptcy court.
Bankruptcy rumors began infiltrating the Oklahoma trial last month. The case, filed on 2017, alleged that Purdue and two other opioid manufacturers, Johnson & Johnson's Janssen Pharmaceuticals Inc. and Teva Pharmaceuticals USA, helped create an epidemic over the prescription painkillers by marketing them as a safe and non-additive treatment for chronic pain.
On Feb. 14, Cleveland County District Court Judge Thad Balkman ordered both sides to submit briefs on whether he had the legal authority to sever the claims against all three defendants and consolidate them for trial—a move that Purdue called an “unprecedented procedural tactic” pushed by the attorney general's office to head off concerns about its imminent bankruptcy.
“Yet Purdue is still here—ready, willing, and eager to prove in this court that the state's claims are baseless,” Purdue's lawyers wrote Feb. 22.
Purdue, and the other defendants, in separate motions, supported severing the claims but not consolidating them for trial, which would be premature and prejudicial. In fact, Teva filed a motion for severance Feb. 26, arguing that a trial with all defendants would be unfair. Among other things, the motion says, the case alleges that Purdue—and, more specifically, its private owners, the Sackler family—first created the epidemic when introducing OxyContin in 1996, five years before Teva's products hit the market.
“The state's focus on Purdue throughout this case has been marked by extraordinary, inflammatory rhetoric, with the state repeatedly labeling the Purdue defendants 'liars,' 'criminals,' 'above the law,' and just 'bad company,'” wrote Teva's attorneys. “Those statements and other evidence and arguments directed at Purdue cannot be attributed to any other party—but will undoubtedly inflame the jury against all defendants before them at trial.”
Neither Teva attorney Robert McCampbell of GableGotwals in Oklahoma City, nor Johnson & Johnson's lawyer, Benjamin Odom of Odom Sparks & Jones in Norman, Oklahoma, responded to requests for comment.
On Feb. 28, Purdue filed its motion for continuance, and an emergency motion to stay expert deadlines, citing the attorney general's “belated tidal wave of documents” produced in discovery —specifically, nearly 1.6 million pages of documents, nearly double the volume of the entire case so far. In Wednesday's reply, Purdue's lawyers noted much more discovery was missing.
“It is obvious that the state is far behind on its discovery obligations,” they wrote. It is long past time for the state to get going. Defendants cannot be punished for the state's failure to comply with its basic discovery obligations and court orders compelling such discovery.”
A continuance would delay the trial to Sept. 16, but it still would be the first opioid case to go before jurors. On Jan. 29, U.S. District Judge Dan Polster, who is overseeing multidistrict litigation of more than 1,600 lawsuits by cities and counties, rescheduled the first federal trial to Oct. 21.
“There is no reason to move the trial date,” Hunter wrote. “Defendants' attempt to do so with this motion is frivolous, desperate, and disingenuous—as is their last-minute request to once again delay their expert disclosures. This court has been clear: we are going to trial on May 28, 2019.”
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
You Might Like
View All'The Most Peculiar Federal Court in the Country' Comes to Berkeley Law
Focusing an Economic Lens On the Decrease In Federal Civil Jury Trials
Trending Stories
Who Got The Work
Clark Hill members Vincent Roskovensky and Kevin B. Watson have entered appearances for Architectural Steel and Associated Products in a pending environmental lawsuit. The complaint, filed Aug. 27 in Pennsylvania Eastern District Court by Brodsky & Smith on behalf of Hung Trinh, accuses the defendant of discharging polluted stormwater from its steel facility without a permit in violation of the Clean Water Act. The case, assigned to U.S. District Judge Gerald J. Pappert, is 2:24-cv-04490, Trinh v. Architectural Steel And Associated Products, Inc.
Who Got The Work
Michael R. Yellin of Cole Schotz has entered an appearance for S2 d/b/a the Shoe Surgeon, Dominic Chambrone a/k/a Dominic Ciambrone and other defendants in a pending trademark infringement lawsuit. The case, filed July 15 in New York Southern District Court by DLA Piper on behalf of Nike, seeks to enjoin Ciambrone and the other defendants in their attempts to build an 'entire multifaceted' retail empire through their unauthorized use of Nike’s trademark rights. The case, assigned to U.S. District Judge Naomi Reice Buchwald, is 1:24-cv-05307, Nike Inc. v. S2, Inc. et al.
Who Got The Work
Sullivan & Cromwell partner Adam S. Paris has entered an appearance for Orthofix Medical in a pending securities class action arising from a proposed acquisition of SeaSpine by Orthofix. The suit, filed Sept. 6 in California Southern District Court, by Girard Sharp and the Hall Firm, contends that the offering materials and related oral communications contained untrue statements of material fact. According to the complaint, the defendants made a series of misrepresentations about Orthofix’s disclosure controls and internal controls over financial reporting and ethical compliance. The case, assigned to U.S. District Judge Linda Lopez, is 3:24-cv-01593, O'Hara v. Orthofix Medical Inc. et al.
Who Got The Work
Attorneys from Cadwalader, Wickersham & Taft and Pryor Cashman have entered appearances for Diageo Americas Supply d/b/a Ciroc Distilling Co. and Sony Songs, a division of Sony Music Publishing, respectively, in a pending lawsuit. The case was filed Sept. 10 in New York Southern District Court by the Bloom Firm and IP Legal Studio on behalf of Dawn Angelique Richard. The plaintiff, who performed as a member of producer Sean 'Diddy' Combs girl group Danity Kane and later his band, Diddy - Dirty Money, claims that she was financially exploited by Combs and subjected to inhumane working conditions. Among other violations, Richard claims that Combs required group members to remain at his residences and studios, deprived them of adequate food and sleep and forced them to rehearse for 36 to 48 hours without breaks. The case, assigned to U.S. District Judge Katherine Polk Failla, is 1:24-cv-06848, Richard v. Combs et al.
Who Got The Work
Mathilda McGee-Tubb and Kevin M. McGinty of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, as well as Jesse W. Belcher-Timme of Doherty, Wallace, Pillsbury & Murphy, have stepped in to defend Peter Pan Bus Lines in a pending consumer class action. The suit, filed Sept. 4 in Massachusetts District Court by Hackett Feinberg PC and KalielGold PLLC, accuses the defendant of charging undisclosed 'junk fees' on top of ticket prices during checkout. The case, assigned to U.S. District Judge Mark G. Mastroianni, is 3:24-cv-12277, Mulani et al v. Peter Pan Bus Lines, Inc.
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250